MONOPAR THERAPEUTICS INC (MNPR)
US61023L1089 - Common Stock
MONOPAR THERAPEUTICS INC
NASDAQ:MNPR (11/15/2024, 8:26:31 PM)
After market: 17.6 -0.49 (-2.71%)18.09
-0.14 (-0.77%)
Company Profile
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois and currently employs 10 full-time employees. The company went IPO on 2019-12-19. The firm is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The firm has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
Company Info
MONOPAR THERAPEUTICS INC
1000 Skokie Blvd Ste 350
Wilmette ILLINOIS 60091
P: 18473880349
CEO: Chandler Robinson
Employees: 10
Website: https://www.monopartx.com/
MNPR News
9 days ago - Monopar Therapeutics Inc.Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments9 days ago - Monopar Therapeutics Inc.Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent DevelopmentsIn-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active...
18 days ago - Monopar Therapeutics Inc.Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common StockWILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage...
20 days ago - Monopar Therapeutics Inc.Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock20 days ago - Monopar Therapeutics Inc.Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common StockWILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage...
20 days ago - ChartmillStay updated with the stocks that are on the move in today's after-hours session.The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.
MNPR Twits
Here you can normally see the latest stock twits on MNPR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
